(19)
(11) EP 2 431 050 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
26.09.2012 Bulletin 2012/39

(43) Date of publication:
21.03.2012 Bulletin 2012/12

(21) Application number: 11184743.0

(22) Date of filing: 20.05.2005
(51) International Patent Classification (IPC): 
A61K 38/20(2006.01)
C07K 16/28(2006.01)
 A61K 39/395(2006.01)
C07K 16/32(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 20.05.2004 US 572973 P
10.12.2004 US 635380 P
14.04.2005 US 671281 P
12.05.2005 US 680447 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
05756320.7 / 1758610

(71) Applicant: ZymoGenetics, Inc.
Seattle, Washington 98102 (US)

(72) Inventors:
  • Kindsvogel, Wayne, R.
    Seattle, WA 98115 (US)
  • Hughes, Steven D.
    Kenmore, WA 98028 (US)
  • Holly, Richard D.
    Seattle, WA 98177 (US)
  • Clegg, Christopher H.
    Seattle, WA 98177 (US)
  • Foster, Donald C.
    Lake Forest Park, WA 98155 (US)
  • Johnson, Rebecca A.
    Seattle, WA 98136 (US)
  • Heipel, Mark D.
    Seattle, WA 98177 (US)
  • Sivakumar, Pallavur V.
    Seattle, WA 98112 (US)

(74) Representative: Griffin, Philippa Jane 
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ
London EC1N 2SQ (GB)

 
Remarks:
This application was filed on 11-10-2011 as a divisional application to the application mentioned under INID code 62.
 


(54) Methods of treating cancer using IL-21 and monoclonal antibody therapy


(57) There is provided a monoclonal antibody that binds to a Her-2/neu receptor, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject, wherein the subject has 1+ or 2+ overexpression levels of the Her-2/neu receptor